{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["15(5)"],"submitter":["Jia H"],"pubmed_abstract":["Herein we describe the medicinal chemistry efforts that led to the discovery of the clinical-staged Syk inhibitor sovleplenib (<b>41</b>) via a structure-activity relationship investigation and pharmacokinetics (PK) optimization of a pyrido[3,4-<i>b</i>]pyrazine scaffold. Sovleplenib is a potent and selective Syk inhibitor with favorable preclinical PK profiles and robust anti-inflammation efficacy in a preclinical collagen-induced arthritis model. Sovleplenib is now being developed for treating autoimmune diseases such as immune thrombocytopenic purpura and warm antibody hemolytic anemia as well as hematological malignancies."],"journal":["ACS medicinal chemistry letters"],"pagination":["595-601"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11089545"],"repository":["biostudies-literature"],"pubmed_title":["Discovery of Sovleplenib, a Selective Inhibitor of Syk in Clinical Development for Autoimmune Diseases and Cancers."],"pmcid":["PMC11089545"],"pubmed_authors":["Cai M","Jia H","Wang G","Xia S","Wang J","Dai X","Li N","Wu Z","He W","Dai G","Cai Y","Guo D","Hao B","Deng W","Su W"],"additional_accession":[]},"is_claimable":false,"name":"Discovery of Sovleplenib, a Selective Inhibitor of Syk in Clinical Development for Autoimmune Diseases and Cancers.","description":"Herein we describe the medicinal chemistry efforts that led to the discovery of the clinical-staged Syk inhibitor sovleplenib (<b>41</b>) via a structure-activity relationship investigation and pharmacokinetics (PK) optimization of a pyrido[3,4-<i>b</i>]pyrazine scaffold. Sovleplenib is a potent and selective Syk inhibitor with favorable preclinical PK profiles and robust anti-inflammation efficacy in a preclinical collagen-induced arthritis model. Sovleplenib is now being developed for treating autoimmune diseases such as immune thrombocytopenic purpura and warm antibody hemolytic anemia as well as hematological malignancies.","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 May","modification":"2026-06-02T21:01:11.499Z","creation":"2026-04-20T03:14:18.237Z"},"accession":"S-EPMC11089545","cross_references":{"pubmed":["38746892"],"doi":["10.1021/acsmedchemlett.3c00553"]}}